1. Molecular basis for Jagged-1/Serrate ligand recognition by the Notch receptor
- Author
-
Paul H. Taylor, Demin Li, Rebecca Heslop, Penny A. Handford, Pat Whiteman, Adrian L. Harris, Christina Redfield, Nattnee Viticheep, Beatriz Hernandez de Madrid, Susan M. Lea, Martin Baron, Ji-Liang Li, Juliana Callaghan, Hideyuki Shimizu, Massimo Masiero, Joyce Zi Tan, and Alison H. Banham
- Subjects
Models, Molecular ,Notch ,Blotting, Western ,Molecular Sequence Data ,Notch signaling pathway ,Plasma protein binding ,Biology ,Ligands ,Biochemistry ,Protein Structure, Secondary ,Cell Line ,Mice ,Serrate-Jagged Proteins ,Cell Line, Tumor ,Animals ,Drosophila Proteins ,Humans ,Amino Acid Sequence ,Binding site ,Receptor, Notch1 ,Molecular Biology ,Peptide sequence ,EGF Domain ,Notch Receptor ,Receptors, Notch ,Sequence Homology, Amino Acid ,HEK 293 cells ,Calcium-Binding Proteins ,Antibodies, Monoclonal ,Membrane Proteins ,Cell Biology ,Flow Cytometry ,Notch Pathway ,Signaling ,Cell biology ,Protein Structure, Tertiary ,HEK293 Cells ,Notch proteins ,Mutation ,DSL Domain ,Jagged-1 Protein ,Intercellular Signaling Peptides and Proteins ,Jagged ,Serrate ,Protein Binding ,Signal Transduction - Abstract
Background: The site of Jagged/Serrate ligand recognition by Notch is unknown. Results: Two critical residues involved in an intramolecular hydrophobic interaction across the central β-sheet of EGF12 form a ligand-binding platform. Conclusion: The ligand-binding region is adjacent to a Fringe-sensitive residue involved in modulating Notch activity. Significance: The results have implications for understanding receptor/ligand recognition, Notch regulation by O-glycosylation, and the development of paralogue-specific antibodies., We have mapped a Jagged/Serrate-binding site to specific residues within the 12th EGF domain of human and Drosophila Notch. Two critical residues, involved in a hydrophobic interaction, provide a ligand-binding platform and are adjacent to a Fringe-sensitive residue that modulates Notch activity. Our data suggest that small variations within the binding site fine-tune ligand specificity, which may explain the observed sequence heterogeneity in mammalian Notch paralogues, and should allow the development of paralogue-specific ligand-blocking antibodies. As a proof of principle, we have generated a Notch-1-specific monoclonal antibody that blocks binding, thus paving the way for antibody tools for research and therapeutic applications.
- Published
- 2016
- Full Text
- View/download PDF